青黄散为主治疗伴有原始细胞增多的骨髓增生异常综合征远期疗效的初步观察  

Study of the long-term efficacy of Qinghuang Powder on reating MDS-RAEB

作　　者：高飞[1] 麻柔[1] 胡晓梅[1] 杨晓红[1] 孙淑贞[1] 王洪志[1] 

机构地区：[1]中国中医科学院西苑医院血液科,北京100091

出　　处：《临床血液学杂志》2013年第1期16-18,共3页Journal of Clinical Hematology

基　　金：国家自然科学基金资助项目(No:30973903)

摘　　要：目的:探讨青黄散为主治疗伴有原始细胞增多的骨髓增生异常综合征(MDS-RAEB)的远期疗效。方法:对30例MDS-RAEB患者采用青黄散为主进行治疗并评价疗效,同时观察患者治疗前后危度等级、骨髓原始细胞、生存时间及肝、肾功能等安全性指标。结果:青黄散为主治疗MDS-RAEB总有效率为56.67%;治疗后患者危度评分明显降低(P<0.05);骨髓原始细胞百分率减低(P<0.05)。截止到观察结束时,全部30例患者均存活,平均已存活时间(28.53±20.43)个月,不同危度等级患者平均已存活时间差异无统计学意义(P>0.05),无一例患者转为AML。结论:青黄散加健脾补肾中药能够有效治疗MDS-RAEB,具有降低患者疾病危度等级、减低骨髓原始细胞、延长MDS-RAEB患者生存时间的作用。Objective：To investigate the long-term efficacy of Qinghuang Powder on treating MDS-RAEB.Method：We Observed 30 out-patients with MDS-RAEB,treated them mainly with Qinghuang Powder,and then evaluated the efficacy.We observed the risk level,bone marrow blast cells,survival time and safety indicators such as liver and renal function before and after treatment as well.Result：The total effective rate of this treatment program was 56.67 percent;the risk score and bone marrow blast cells decreased significantly after treatment（P0.05）.At the end of the observation,all 30 patients were alive without anyone converting to AML.They had an average survival time of 28.53±20.43 months,and there was no difference in patients with different risk levels by statistics（P0.05）.Conclusion：It was effective to treat patients with MDS-RAEB by Qinghuang Powder jointly with Chinese medicine of stronging spleen and kidney.They can decrease the disease risk level,the bone marrow blast cells,and can extend the survival time of patients with MDS-RAEB.

关 键 词：骨髓增生异常综合征 青黄散 生存时间 

分 类 号：R551.3[医药卫生—血液循环系统疾病]